Sedivention GmbH
Entry last updated on April 20, 2023

Severe obesity causes more than 400,000 deaths annually and costs society over $2 trillion worldwide. Yet, a scalable, affordable, and easily accessible treatment remains lacking. The idea behind Sedivention is to develop a widely applicable interventional therapy comparable to gastroscopy.

Hunger is one of the main drivers of overeating and obesity. Hunger is transmitted to the brain via the vagus nerve. Sedivention is developing a cryoballoon that obliterates the vagus nerve from the stomach. This outpatient procedure takes approximately 20 minutes, costs significantly less than gastric sleeve surgery, and does so without the morbidity and complications.

In brief: Sedivention is developing the first effective and scalable treatment for obesity. No scars, no pain, no surgical complications, no barriers to access, no implants, and at an affordable price.

Show English Description

Facts
 
Contact
 

2

Founders

2021

Founding year

Seed stage

Stage

B2B

Business model

Company location

Sedivention GmbH
Hugo-Hofmann-Str. 56
82064 Strasslach

[AdditionalInfo]
[Fundings] [Analytics] [Insights]

You might also be interested in

Sedivention

Deals

800,000 euros pre-seed financing for Sedivention

The early-stage investor High-Tech Gründerfonds (HTGF) is investing €800,000 in Sedivention as part of a pre-seed financing round. The medtech startup is developing a medical device that…

Sedivention

Inside Stories

Sedivention: Novel therapy for obesity

The Munich-based medtech company Sedivention aims to facilitate the treatment of obesity with a novel catheter – an approach the company has already used…

THEVA

News

Fresh capital for THEVA GmbH

BayBG is investing in the production of superconductors, or more precisely, in THEVA GmbH. It was able to…